dc.contributor.author | Ergüven, M. | |
dc.contributor.author | Bilir, A. | |
dc.date.accessioned | 2021-12-21T08:41:55Z | |
dc.date.available | 2021-12-21T08:41:55Z | |
dc.date.issued | 2012 | |
dc.identifier.isbn | 9789400742345; 9400742339; 9789400742338 | |
dc.identifier.uri | https://doi.org/10.1007/978-94-007-4234-5_25 | |
dc.identifier.uri | http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/1549 | |
dc.description.abstract | Glioblastoma (GBM) is the most common and lethal brain tumor. Characterization of GBM with poor prognosis although new treatment modalities hasn't been changed up to date. New molecular targets in order to overcome resistance and recurrence are needed. Au | |
dc.language.iso | English | |
dc.publisher | Springer Netherlands | |
dc.title | Midkine in glioblastoma with the modulator role switching autophagy to cell death or cell survival | |
dc.type | Book Chapter | |
dc.relation.journal | Midkine: From Embryogenesis to Pathogenesis and Therapy | |
dc.identifier.startpage | 283 | |
dc.identifier.endpage | 303 | |
dc.identifier.doi | 10.1007/978-94-007-4234-5_25 | |